Comparative Pharmacology
Head-to-head clinical analysis: NUZYRA versus SEYSARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUZYRA versus SEYSARA.
NUZYRA vs SEYSARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic